We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Endoscopic Treatment Could Spare Surgery in Barrett's Esophagus Patients

By HospiMedica International staff writers
Posted on 02 Mar 2010
A new study has found that early tumor formation in Barrett''s esophagus (BE) can be effectively and safely treated with radiofrequency ablation (RFA), in combination with prior endoscopic removal of visible lesions.

Researchers from the University of Amsterdam (UVA; The Netherlands), Evangelisches Krankenhaus (Düsseldorf, Germany), and Erasme University Hospital (Brussels, Belgium) conducted a multicenter, prospective cohort study that included 24 patients (mean age 65), with BE less or equal to 12 cm containing high-grade intraepithelial neoplasia (HGIN) or early cancer.

Visible lesions were endoscopically resected, followed by serial RFA; focal escape endoscopic resection was used if Barrett tissue persisted despite RFA. More...
Complete response, defined as all biopsies negative for intestinal metaplasia and neoplasia, and was assessed during endoscopy with four-quadrant biopsies taken for every one centimeter of the original Barrett's segment, two months after the patient was last treated.

The results showed that of the 23 patients that underwent pre-RFA endoscopic resection for visible lesions, 16 patients had early cancer and seven patients had HGIN. The worst residual histology results, pre-RFA (and after any endoscopic resection) were HGIN (10 patients), low-grade intraepithelial neoplasia (11 patients), and intestinal metaplasia (three patients). Neoplasia and intestinal metaplasia were eradicated in 95% and 88% of patients, respectively; after escape endoscopic resection in two of the patients, rates improved to 100% and 96%, respectively. After additional follow-up for a median period of 22 months, no neoplasia had recurred. The study was published in the January 2010 issue of the journal Clinical Gastroenterology and Hepatology.

"Combining endoscopic resection with complete removal of residual Barrett cells with radiofrequency ablation may decrease the recurrence of lesion formation, and could potentially limit the number of Barrett's esophagus cases that progress to esophageal cancer,” said lead author Jacques Bergman, M.D., of the Academic Medical Center at UVA.

Currently, the cornerstone of treatment of early BE tumors are endoscopic resection in which visible lesions are removed, and tumor infiltration depth and differentiation are assessed. After focal endoscopic resection, however, the residual Barrett mucosa remains at risk for malignant transformation and cancer recurrences are found in 30% of patients during follow-up. To prevent such lesions, newer endoscopic approaches, including RFA, have been studied in an attempt to eradicate the residual Barrett mucosa.

Related Links:

University of Amsterdam
Evangelisches Krankenhaus
Erasme University Hospital



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Half Apron
Demi
Emergency Ventilator
Shangrila935
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.